Jeongwon Choi is a Nephrology physician affiliated with Catholic Medical Center. OpenAlex indexes 51 publications with 1,069 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Jose Figueres Ave Ste 255
San Jose, CA 951161589
Telephone
408-223-7474Provider last certified this registry record 12 Feb 2026.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Fresenius USA Marketing, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Travere Therapeutics, Inc.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.7%Calcium channel blocker19.1%Amlodipine Besylate69%Nifedipine Er31%Part D≥24 patientsBeta blocker13.2%Carvedilol74%Metoprolol Succinate26%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
15.1%SGLT2 inhibitor9.9%Jardiance73%Farxiga27%Part D<11 patientsProton pump inhibitor3.1%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Other
9.9%Phosphate Binder9.9%Sevelamer Carbonate100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- MicroRNA-21a-5p inhibition alleviates systemic sclerosis by targeting STAT3 signaling
Journal of Translational Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Aviram Hochstadt, MD, MPH
Catholic Medical Center
Yvon Baribeau, MD
Catholic Medical Center
Aaqib Malik, MD, BSC, MPH
Catholic Medical Center
Gerald Sardella, MD, FACS
Catholic Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”